ALZAMEND NEURO INC (ALZN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.66-2.35%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ALZN
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 | Apr 2020 | |
|---|---|---|---|---|---|---|---|---|
| Operating Expenses & Income | ||||||||
| R&D Expenses | 3.6 | 3.6 | 1.4 | 6.5 | 7.4 | 5.2 | 1.3 | 1.1 |
| Operating Income | (8.8) | (8.8) | (4.5) | (9.9) | (14.9) | (12.3) | (5.0) | (4.4) |
| Earnings from Continuing Operations | ||||||||
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | — |
| Interest & Investment Income | — | 0.0 | — | — | — | — | — | — |
| Other Non-Operating Income / Expenses | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.1) | 0.0 |
| EBT, Incl. Unusual Items | — | (8.8) | (4.5) | (9.9) | (14.9) | (12.4) | (5.0) | (4.4) |
| Net Income | ||||||||
| Net Income | (8.8) | (8.8) | (4.5) | (9.9) | (14.9) | (12.4) | (5.0) | (4.4) |
| Per Share | ||||||||
| Basic EPS | — | (2.63) | (11.32) | (14.70) | (22.89) | (0.14) | — | — |
| Diluted EPS | — | (2.63) | (11.32) | (14.70) | (22.89) | (0.14) | — | — |
| Basic Weighted Avg Shares | — | 3.3 | 0.5 | 0.7 | 0.7 | 89.1 | 72.7 | — |
| Diluted Weighted Avg Shares | — | 3.3 | 0.5 | 0.7 | 0.7 | 89.1 | — | — |
| Supplemental | ||||||||
| EBIT | (8.8) | (8.8) | (4.5) | (9.9) | (14.9) | (12.3) | (5.0) | (4.4) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.